4th December, 2019

 Spirea Ltd today announced that it is delighted to have received pre-seed funding from the University of Cambridge Enterprise Seed Funds. The funding will be used to further optimise Spirea’s approach to the development of safe and effective antibody drug conjugates for use in cancer therapeutics, and to further strengthen the company’s intellectual property position. Dr Myriam Ouberai, CEO of Spirea, commented, “I am grateful for the support and advice of Cambridge Enterprise and very much look forward to continuing to work with them as Spirea evolves into a successful ADC development organisation.”